SIC
FULC icon

SJS Investment Consulting’s Fulcrum Therapeutics FULC Stock Holding History

SJS Investment Consulting’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$583 Buy
76
+73
+2,433% +$677 ﹤0.01% 1672
2025
Q4 		$34 Buy
+3
New +$31 ﹤0.01% 2046

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SJS Investment Consulting's FULC Position: Q1 2026 in Review

SJS Investment Consulting increased its Fulcrum Therapeutics (FULC) stake by 2,433% in Q1 2026, buying an estimated $677 and bringing the position to 76 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

SJS Investment Consulting first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • SJS Investment Consulting held 76 shares of Fulcrum Therapeutics worth $583 as of Q1 2026.
  • SJS Investment Consulting bought 73 Fulcrum Therapeutics shares in Q1 2026, an estimated $677.
  • Fulcrum Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #1672 holding.
  • SJS Investment Consulting first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.